ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1150

Impact of IL-17A on synovial fibroblast from subacromial bursae

Andre Ramon1, Hélène Greigert2, baptiste lamarthée3, Corentin Richard4, claudie Cladière3, Noemie Klopfenstein3, Ludovic Labattut5, Alice Bordet5, Sylvain Audia6, Romain boidot4, jean-francis Maillefert1, Bernard Bonnotte7 and Maxime Samson8, 1Rheumatology, Université Bourgogne Europe, CHU Dijon Bourgogne, Dijon, France, 2Vascular Medicine, Université Bourgogne Europe, CHU Dijon Bourgogne, Dijon, France, 3Marie et Louis Pasteur University, EFS, INSERM, UMR RIGHT, Besançon, France, Dijon, France, 4Molecular Biology Unit, Georges-François Leclerc Cancer Center, UNICANCER, Dijon, France, Dijon, France, 5Orthopedic Surgery, Université Bourgogne Europe, CHU Dijon Bourgogne, Dijon, France, 6Internal Medicine and Clinical Immunology, Université Bourgogne Europe, CHU Dijon Bourgogne, Dijon, France, 7Internal medicine and clinical immunology, Université Bourgogne Europe , CHU Dijon Bourgogne, Dijon, France, 8CHU Dijon Bourgogne, Dijon, France

Meeting: ACR Convergence 2025

Keywords: cytokines, Fibroblasts, Synovial, Polymyalgia Rheumatica (PMR)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Polymyalgia rheumatica (PMR) is characterized by increases in serum IL-6 and the proportion of Th17 cells in circulating blood. During PMR, IL-6 may originate from circulating monocytes or from the synovial tissue itself. To clarify the role of synovial tissue, we performed experiments using synovial fibroblast (SF) cultures derived from synovial bursae, which are the affected structures in PMR. As secukinumab (SEC) is currently being evaluated in glucocorticoid-dependent PMR, we investigated, in the current study, the impact of IL-17A and SEC on SFs activation.

Methods: SFs were obtained from ex-vivo cultures of synovial tissue from the subacromial bursae after arthroscopy in patients with rotator cuff injury. SFs were cultivated in vitro with IL-17A (50 ng/mL), IFN-g (2.5 ng/mL) and/or SEC (20 µg/mL) for 24 hours. mRNA expression was analyzed by Bulk RNA sequencing and RT-PCR. The impact of IL-17A on T-cell polarization was assessed by performing co-cultures of SFs and allogenic peripheral blood mononuclear cells (PBMC) activated with anti CD3/CD28 beads. SFs were stimulated with IL-17A or IL-17A + SEC or IgG isotype control for 72 hours, then co-cultures were performed over 7 days. T-cell polarization was analyzed by flow cytometry.

Results: The cells obtained through synovial tissue culture exhibited a phenotype fitting with fibroblasts (CD90+CD105+CD73intCD34-CD45-). Bulk RNA sequencing analysis showed increased levels of expression for genes associated with IL-17, PI3k-Akt and the NF-KB signaling pathway. Stimulation with IL-17A led to significant increases in 28 genes, notably IL6, CSF2 (encoding for GM-CSF), and CCL2. The addition of SEC led to a significant decrease in these mRNAs, restoring a transcriptomic profile similar to unstimulated SF (figure 1). RT-PCR analyses confirmed an increase in the mRNA expression of IL6, CSF2 and CCL2 in the presence of IL-17A, while no difference was observed for IL6ST, IFNGR1/2, IL12A, IL23A, FAP, IL17RA and IL17RC mRNA. Co-stimulation with IL-17A and IFN-g led to a strong increase in mRNA expression of IL6, IL6ST, and CCL2 (figure 2A). This synergy between IL-17A and IFN-g may be reliant on an increase in IL17RA mRNA expression after IFN-g stimulation (figure 2B). Co-cultures of SFs with allogenic PBMC were performed after 72h of SFs stimulation with either IgG isotype control, IL-17A or IL-17A+SEC. Compared to SFs pre-treated with IgG or IL-17A+SEC, SFs pre-treated with IL-17A were able to promote Th17 cell polarization without significant increases in the proportions of Th1, Tc1 or Tc17 cells (figure 3).

Conclusion: This work highlights the potential role of SFs in PMR via their ability to strongly express IL6. SFs are also sensitive to IL-17A and IFN-y, which are two key cytokines in PMR. In response to IL-17A, and with a synergistic effect with IFN-y, SFs strongly express IL6, leading to an increase in Th17 polarization. In addition, SFs express other markers such as CCL2, suggesting that they may induce the recruitment of CCR2+ monocytes. Finally, SEC can restore a non-inflammatory profile in activated SF, suggesting the potential of IL-17A therapeutic target in PMR.

Supporting image 1Figure 1: Bulk RNA sequencing results from IL-17A stimulated synovial fibroblasts (n = 8).

(A) Volcano plot showing differential gene expression (IL-17A versus IgG; IL-17A + SEC versus IgG).

(B) Barplot visualization of IL6, CSF2 and CCL2 gene expression from IL-17A, IL-17A + SEC and IgG stimulated synovial fibroblasts. Columns represent the median, the “whiskers” represent quartiles Q1 and Q3. *: p < 0.05, **: p < 0.01.

Supporting image 2Figure 2: Level of mRNA expression of IL6, IL6ST, CCL2 and IL17RA by synovial fibroblasts after stimulation with IL-17A and/or IFN-γ (n = 9).

A: Level of mRNA expression of IL6, IL6ST and CCL2 in synovial fibroblasts after stimulation with IL-17A (50 ng/mL) and/or IFN-γ (2,5 ng/mL). B: Effect of IFN-γ on mRNA expression of IL17RA by synovial fibroblasts. Columns represent the median, the “whiskers” represent quartiles Q1 and Q3. *: p < 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001

Supporting image 3Figure 3: Study of the effect of synovial fibroblasts on T-cell polarization.

Percentage of Th1 (CD4+CD8-IFN-γ+), Tc1 (CD4-CD8+ IFN-γ-), Th17 (CD4+CD8-IL-17+), and Tc17 (CD4-CD8+IL-17+) cells. Columns represent the median, the “whiskers” represent quartiles Q1 and Q3. *: p < 0.05, ***: p < 0.001. NS = not significant. SEC: secukinumab. Coculture was performed using 8 samples of synovial tissue.


Disclosures: A. Ramon: AbbVie/Abbott, 2, Boehringer-Ingelheim, 2, chugai, 2, Novartis, 2, 5; H. Greigert: None; b. lamarthée: None; C. Richard: None; c. Cladière: None; N. Klopfenstein: None; L. Labattut: None; A. Bordet: None; S. Audia: None; R. boidot: None; j. Maillefert: None; B. Bonnotte: Boehringer-Ingelheim, 2, Chugai, 2, Novartis, 2, Vifor Pharma, 2; M. Samson: AbbVie/Abbott, 2, AstraZeneca, 2, Boehringer-Ingelheim, 2, Chugai, 2, Fresenius Kabi, 2, GlaxoSmithKlein(GSK), 2, Novartis, 2, 5, Vifor Pharma, 2.

To cite this abstract in AMA style:

Ramon A, Greigert H, lamarthée b, Richard C, Cladière c, Klopfenstein N, Labattut L, Bordet A, Audia S, boidot R, Maillefert j, Bonnotte B, Samson M. Impact of IL-17A on synovial fibroblast from subacromial bursae [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/impact-of-il-17a-on-synovial-fibroblast-from-subacromial-bursae/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-il-17a-on-synovial-fibroblast-from-subacromial-bursae/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology